On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Sanofi India has increased 9.74% to Rs 514.9 crore. Operating profit margin has jumped from 21.23% to 22.98%, leading to 18.78% rise in operating profit to Rs 118.30 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 17.17% to 16.94%. Purchase of finished goods cost rose from 28.03% to 39.34%. Employee cost decreased from 15.90% to 8.87%. Other expenses fell from 17.04% to 15.34%. Other income fell 37.23% to Rs 5.9 crore. PBIDT rose 13.94% to Rs 124.2 crore. Loan funds rose to Rs 19.30 crore as of 31 December 2024 from Rs 19.00 crore as of 31 December 2023. Inventories declined from Rs 663.80 crore as of 31 December 2023 to Rs 499.80 crore as of 31 December 2024. Sundry debtors were higher at Rs 230.00 crore as of 31 December 2024 compared to Rs 131.70 crore as of 31 December 2023. Cash and bank balance declined from Rs 406.50 crore as of 31 December 2023 to Rs 294.80 crore as of 31 December 2024. PBDT rose 14% to Rs 123.8 crore. Provision for depreciation rose 3.23% to Rs 9.6 crore. Fixed assets increased to Rs 329.30 crore as of 31 December 2024 from Rs 323.30 crore as of 31 December 2023. Intangible assets declined from Rs 7.50 crore to Rs 1.30 crore. Profit before tax grew 15.01% to Rs 114.20 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 30.9 crore, compared to Rs 29.6 crore. Effective tax rate was 25.29% compared to 29.81%. Minority interest was nil in both the periods. Net profit attributable to owners of the company increased 30.99% to Rs 91.30 crore. Equity capital stood at Rs 23.00 crore as of 31 December 2024 to Rs 23.00 crore as of 31 December 2023. Per share face Value remained same at Rs 10.00. Promoters’ stake was 60.40% as of 31 December 2024 ,compared to 60.40% as of 31 December 2023 .
Full year results analysis.
Net sales (including other operating income) of Sanofi India has increased 0.86% to Rs 2013.2 crore. Operating profit margin has declined from 24.43% to 24.38%, leading to 0.64% rise in operating profit to Rs 490.80 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 15.08% to 18.17%. Purchase of finished goods cost fell from 39.18% to 28.89%. Employee cost decreased from 12.31% to 12.30%. Other expenses rose from 12.03% to 15.51%. Other income fell 73.04% to Rs 16.5 crore. PBIDT fell 7.58% to Rs 507.3 crore. Provision for interest fell 11.76% to Rs 1.5 crore. Loan funds rose to Rs 19.30 crore as of 31 December 2024 from Rs 19.00 crore as of 31 December 2023. Inventories declined from Rs 663.80 crore as of 31 December 2023 to Rs 499.80 crore as of 31 December 2024. Sundry debtors were higher at Rs 230.00 crore as of 31 December 2024 compared to Rs 131.70 crore as of 31 December 2023. Cash and bank balance declined from Rs 406.50 crore as of 31 December 2023 to Rs 294.80 crore as of 31 December 2024. PBDT fell 7.57% to Rs 505.8 crore. Provision for depreciation rose 0.55% to Rs 36.7 crore. Fixed assets increased to Rs 329.30 crore as of 31 December 2024 from Rs 323.30 crore as of 31 December 2023. Intangible assets declined from Rs 7.50 crore to Rs 1.30 crore. Profit before tax down 8.15% to Rs 469.10 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 117.7 crore, compared to Rs 163.9 crore. Effective tax rate was 27.28% compared to 31.01%. Minority interest was nil in both the periods. Net profit attributable to owners of the company decreased 13.96% to Rs 313.70 crore. Equity capital stood at Rs 23.00 crore as of 31 December 2024 to Rs 23.00 crore as of 31 December 2023. Per share face Value remained same at Rs 10.00. Promoters’ stake was 60.40% as of 31 December 2024 ,compared to 60.40% as of 31 December 2023 . Other Highlights
The board recommended a final dividend of
Rs 117 per equity share of the face value of Rs 10 each for the Financial Year
ended 31st December 2024.
Management Comments :
Rodolfo Hrosz, Managing Director of Sanofi
India said, “In a year of significant transformation for the company, we have
successfully brought to market Soliqua® - our best-in-class diabetes drug for
the premix segment, which has received encouraging acceptance. Our efforts of
reaching more HCPs through partnerships for the Cardiovascular and CNS (Central
Nervous System) categories have advanced as planned, with initial promising
results. We will continue to focus on driving further improvement in operating
efficiencies while expanding the availability of established and innovative
products in India.”
| Sanofi India : Consolidated Results | | | Quarter ended | Year ended |
|---|
| Particulars | 202412 | 202312 | Var.(%) | 202412 | 202312 | Var.(%) |
|---|
| Net Sales (including other operating income) | 514.90 | 469.20 | 9.74 | 2,013.20 | 1,996.10 | 0.86 | | OPM (%) | 22.98 | 21.23 | 175 bps | 24.38 | 24.43 | -5 bps | | OP | 118.30 | 99.60 | 18.78 | 490.80 | 487.70 | 0.64 | | Other Inc. | 5.90 | 9.40 | -37.23 | 16.50 | 61.20 | -73.04 | | PBIDT | 124.20 | 109.00 | 13.94 | 507.30 | 548.90 | -7.58 | | Interest | 0.40 | 0.40 | 0 | 1.50 | 1.70 | -11.76 | | PBDT | 123.80 | 108.60 | 14.00 | 505.80 | 547.20 | -7.57 | | Depreciation | 9.6 | 9.3 | 3.23 | 36.7 | 36.5 | 0.55 | | PBT | 114.20 | 99.30 | 15.01 | 469.1 | 510.7 | -8.15 | | Share of Profit/(Loss) from Associates | 0 | 0 | - | 0 | 0 | - | | PBT before EO | 114.2 | 99.3 | 15.01 | 469.1 | 510.7 | -8.15 | | EO Income | 8 | 0 | - | -37.7 | 17.8 | PL | | PBT after EO | 122.2 | 99.3 | 23.06 | 431.4 | 528.5 | -18.37 | | Taxation | 30.9 | 29.6 | 4.39 | 117.7 | 163.9 | -28.19 | | PAT | 91.3 | 69.7 | 30.99 | 313.7 | 364.6 | -13.96 | | Minority Interest (MI) | 0 | 0 | - | 0 | 0 | - | | Net profit | 91.3 | 69.7 | 30.99 | 313.7 | 364.6 | -13.96 | | P/(L) from discontinued operations net of tax | 0 | 68 | - | 99.6 | 238.3 | -58.20 | | Net profit after discontinued operations | 91.3 | 137.7 | -33.70 | 413.3 | 602.9 | -31.45 | | EPS (Rs)* | 37.05 | 30.26 | 22.41 | 148.12 | 152.98 | -3.18 | | | * EPS is on current equity of Rs 23.03 crore, Face value of Rs 10, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|